Proteon Therapeutics to Present at the Cowen and Company 36th Annual Health Care Conference on March 8th

WALTHAM, Mass., March 02, 2016 -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, announced today that Company management will present at the Cowen and Company 36^th Annual Health Care Conference in Boston on Tuesday, March 8, 2016, at 8:40 am ET.

About Proteon Therapeutics
Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon’s lead product candidate, vonapanitase (formerly PRT-201), is an investigational drug intended to improve arteriovenous fistula (AVF) patency, the period of time during which an AVF remains open with adequate blood flow to enable hemodialysis. Proteon is currently evaluating vonapanitase in two Phase 3 clinical trials in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic AVF for hemodialysis and has completed a Phase 1 clinical trial in patients with symptomatic peripheral artery disease (PAD). For more information, please visit www.proteontherapeutics.com.

Investor Contact 
George Eldridge, Senior Vice President and Chief Financial Officer
781-890-0102
[email protected] 

Press Contact 
Chris Erdman, MacDougall Biomedical Communications
781-235-3060
[email protected]